


Dry Eye Syndrome Treatment Market to Reach USD 10.17 Billion by 2032, Driven by Innovation and Growing Demand

Advancements in AI Diagnostics, Drug-Device Therapies, and Regenerative Medicine are Fueling Market Expansion at a CAGR of 6.32%.

AUSTIN, TX, UNITED STATES, February 20, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The [Dry Eye Syndrome Treatment Market](#) was estimated at USD 5.86 billion in 2023 and is expected to reach USD 10.17 billion by 2032, at a CAGR of 6.32% during the forecast period of 2024-2032.



The Dry Eye Syndrome Treatment Market is expanding with the increasing prevalence of dry eye disease, fueled by reasons like increased screen time, aging, and co-morbidities. This has created a higher demand for novel treatments like lipid-based eye drops and new drug-device therapies. Progress in AI diagnostics, portable treatment devices, and FDA approvals are driving research faster, while collaborations in the industry are broadening the pipeline for better solutions.

Get a Free Sample Report@ <https://www.snsinsider.com/sample-request/5482>

Major Players in Dry Eye Syndrome Treatment Market

- Invacare Corporation (TDX SP2 Power Wheelchair, Rollite Rollator Walker)
- Sunrise Medical (Quickie Q500 M Power Wheelchair, Airgo Comfort-Plus Lightweight Rollator)
- Drive DeVilbiss Healthcare (Titan AXS Electric Wheelchair, Nitro Euro Style Rollator)
- Allergan (Restasis Eye Drops, Refresh Artificial Tears)
- Novartis AG (Xiidra Ophthalmic Solution, Systane Lubricant Eye Drops)
- Johnson & Johnson Vision (Blink Tears, Acuvue Theravision Contact Lenses)
- Bausch + Lomb (Lumify Redness Reliever, Soothe XP Advanced Eye Drops)
- Sun Pharmaceutical Industries Ltd. (Cequa Cyclosporine Eye Drops, Omidria Surgical Solution)
- Santen Pharmaceutical Co., Ltd. (Ikervis Cyclosporine Eye Drops, Hyalein Sodium Hyaluronate)

Drops)

- Hoya Corporation (MiYOSMART Lenses, Vision Simulator Devices)
- Alcon Inc. (Tears Naturale Lubricant Drops, Pataday Allergy Relief Eye Drops)
- Medicom Healthcare Ltd. (Evolve Preservative-Free Drops, Hydrosight Eye Care Solutions)
- Otsuka Pharmaceutical Co., Ltd. (Mucosta Eye Drops, Dryzar Hyaluronic Acid Drops)
- Hikma Pharmaceuticals PLC (Cyclosporine Ophthalmic Emulsion, Artificial Tears Drops)
- Kala Pharmaceuticals, Inc. (Eysuvis for Dry Eye Flares, Inveltys Post-Surgical Drops)
- Regener-Eyes (Regener-Eyes Pro Biologic Drops, Regener-Eyes Lite for Mild Dry Eye)
- Oyster Point Pharma, Inc. (Tyrvaya Nasal Spray, Oyster Therapy Experimental Biologics)
- Abbott Laboratories (Blink GelTears, Moisture Eyes Artificial Tears)
- Croma-Pharma GmbH (EvoTears for Evaporative Dry Eye, EyeSol Stabilized Lipid Drops)
- AFT Pharmaceuticals Ltd. (NovaTears for MGD, Maxigesic Eye Anti-inflammatory)
- Nicox S.A. (Zerviate for Allergic Conjunctivitis, NCX-4251 for Inflammation)
- Akorn, Inc. (Akten Lubricating Drops, HydroEye Nutritional Supplements)
- Scope Ophthalmics (Hycosan Preservative-Free Drops, Optase Moist Heat Mask)

By Treatment Type, the aqueous dry eye segment will grow the fastest over the forecast period.

Because its chronic status is becoming better recognized, and new treatment methods are being developed. Aqueous dry eye has a reduced ability to produce tears, which may be associated with Sjögren's syndrome or age. Consequently, the demand for prescription treatments, including anti-inflammatory drugs, corticosteroids, and newer biologics focused on the treatment of inflammation and tear production, is increasing. As regenerative medicine, gene therapy, and biologics continue to evolve, the aqueous dry eye segment is set for high growth due to heightened R&D focus as well as increased treatment personalization. Additionally, the clearance of new therapies and emphasis on new drug-device combinations are anticipated to fuel additional market growth, filling the unmet needs of aqueous dry eye patients.

By Treatment Product Type, the artificial tears segment dominated the dry eye syndrome treatment market with a 42% market share in 2023

Owing to their broad usage as a first-line drug for dry eye symptom treatment. Artificial tears lubricate the eye and relieve irritation, proving efficient in delivering relief from both minor and moderate forms of dry eye disease. Their low cost, over-the-counter status, and simplicity of use make them extremely convenient for a broad patient population, which is one reason for their dominance. In addition, the range of formulations, such as preservative-free, gel-based, and lipid-based eye drops, enables individualized treatment for varying degrees of severity. Consequently, artificial tears are the preferred treatment for dry eye disease, propelling their market dominance. Also, their ability to address both evaporative and aqueous dry eye signs, in addition to the growing incidence of the condition, attests to their sustained market dominance.

By Sales Channel, the prescription segment dominated the dry eye syndrome treatment market in 2023

Because of the growing incidence of moderate to severe dry eye disease, which tends to necessitate more sophisticated and specific treatments. Prescription drugs, including anti-inflammatory drugs, corticosteroids, and immunosuppressants, are necessary for treating chronic dry eye and long-term symptom management. These medications are generally prescribed by optometrists and ophthalmologists for patients who cannot be treated with over-the-counter products such as artificial tears. Further, increased penetration of more sophisticated prescription therapies such as biologics and gene therapies has supported this segment. With patients looking for more durable solutions for chronic dry eye symptoms, the prescription segment is still driving the dominance of the market.

By Dosage Form, the eye solutions/drops segment dominated the market in 2023

Because they are effective, convenient to use, and in common use to treat dry eye disease. Dry eye is most frequently treated by eye drops with quick relief being provided by the lubrication of the ocular surface and hydration. They are convenient, easily available over-the-counter, and relatively inexpensive. They are hence a patient- and physician's choice for the management of mild and moderate symptoms. Eye drops also have a host of formulations--preservative-free, lipid drops, and medicated drops, which suit many patients' demands. The dominance of the segment is also propelled by the increasing emphasis on innovation in eye drop products, including the launch of drug-device combinations and products with extended durations of action, which have made eye drops a key component of dry eye disease treatment.

Buy Full Research Report on Dry Eye Syndrome Treatment Market 2024-2032 @ <https://www.snsinsider.com/checkout/5482>

North America dominated the dry eye syndrome treatment market with 40% market share in 2023

The dominance is due to a result of its high rate of disease and well-established healthcare infrastructure. The aging population of the region, coupled with rising screen use and environmental stressors, further fuels the increasing demand for the treatment of dry eye. Moreover, the availability of large pharmaceutical organizations, regulatory support for novel treatments, and the robust healthcare infrastructure also enhance the leadership of North America in the market. Public awareness and widespread availability of cutting-edge treatments also lend support to this supremacy.

Asia Pacific will see the fastest growth in the dry eye syndrome treatment market with increased environmental pollution, lifestyle alterations, and rising screen time. The increased occurrence of underlying diseases like diabetes further helps in fueling the market growth. Better healthcare infrastructure increased disposable income, and increasing awareness of dry eye disease in

nations such as China, India, and Japan are propelling the demand for treatments. Furthermore, innovation in medical technology and government initiatives will drive future growth in the region.

Table of Contents – Major Key Points

1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Dry Eye Syndrome Treatment Market by Treatment Type
8. Dry Eye Syndrome Treatment Market by Treatment Drugs
9. Dry Eye Syndrome Treatment Market by Treatment Product
10. Dry Eye Syndrome Treatment Market by Sales Channel
11. Dry Eye Syndrome Treatment Market by Distribution Channel
12. Regional Analysis
13. Company Profiles
14. Use Cases and Best Practices
15. Conclusion

For further insights and customized research on the Dry Eye Syndrome Treatment Market, contact @ <https://www.snsinsider.com/enquiry/5482>

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/787657905>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.